Association Between Type of Vascular Access Used in Hemodialysis Patients and Subsequent Kidney Transplant Outcomes.
Arteriovenous fistula
allograft loss
arteriovenous graft
central venous catheter
kidney transplantation
mortality
Journal
Kidney medicine
ISSN: 2590-0595
Titre abrégé: Kidney Med
Pays: United States
ID NLM: 101756300
Informations de publication
Date de publication:
Historique:
entrez:
1
8
2020
pubmed:
1
8
2020
medline:
1
8
2020
Statut:
epublish
Résumé
Vascular access type (arteriovenous fistula [AVF] vs arteriovenous graft [AVG] vs central venous catheter [CVC]) associates with clinical outcomes in patients with end-stage kidney disease undergoing hemodialysis. Whether a similar association exists with outcomes after kidney transplantation is unknown. We hypothesized that AVGs would associate with worse outcomes, perhaps owing to persistent subclinical inflammation. Retrospective cohort study. Using US registry data merged with electronic health records of a large dialysis organization (2006-2011), we selected patients receiving a first-ever kidney transplant after undergoing more than 30 days of hemodialysis. Hemodialysis access used during the patient's last pretransplantation hemodialysis session. Patients were followed up from kidney transplantation for all-cause mortality, kidney allograft loss from any cause, and allograft loss not from death. Time-to-event analysis including Kaplan-Meier plots and Cox proportional hazards regression estimated cause-specific HRs and 95% CIs. Among 9,291 patients who underwent kidney transplantation between 2006 and 2011, a total of 65.3% used an AVF, 20.4% used an AVG, and 14.3% used a CVC for hemodialysis before transplantation. Multivariable regression models adjusted for demographic variables, comorbid conditions, transplant characteristics, and laboratory parameters identified no independent associations between vascular access type and all-cause mortality (HR Nonrandomized exposure leading to potential residual confounding. No association was found for AVG use before kidney transplantation with mortality, all-cause allograft loss, and allograft loss from all causes other than death, compared with AVF use. The association of CVC use with allograft loss from causes other than death requires further investigation.
Identifiants
pubmed: 32734218
doi: 10.1016/j.xkme.2019.08.005
pii: S2590-0595(19)30119-0
pmc: PMC7384366
doi:
Types de publication
Journal Article
Langues
eng
Pagination
383-390Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK095024
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK095867
Pays : United States
Informations de copyright
© 2019 The Authors.
Références
Am J Kidney Dis. 2002 Oct;40(4):745-52
pubmed: 12324909
Am J Kidney Dis. 2002 Nov;40(5):974-82
pubmed: 12407642
J Vasc Surg. 2015 Jul;62(1):123-7
pubmed: 25769391
Nephrol Dial Transplant. 2011 Nov;26(11):3659-66
pubmed: 21372255
J Vasc Surg. 2016 Jul;64(1):236-43
pubmed: 27345510
Am J Kidney Dis. 1992 Nov;20(5 Suppl 2):68-83
pubmed: 1442778
J Am Soc Nephrol. 2013 Feb;24(3):465-73
pubmed: 23431075
Kidney Int. 2002 Aug;62(2):620-6
pubmed: 12110026
Am J Kidney Dis. 2014 Dec;64(6):954-61
pubmed: 25266479
Nephrol Dial Transplant. 2013 Apr;28(4):770-3
pubmed: 23109559
Kidney Int. 2009 Nov;76(10):1063-9
pubmed: 19675528
Semin Dial. 2008 Sep-Oct;21(5):483-9
pubmed: 18764794
Am J Kidney Dis. 2009 Nov;54(5):912-21
pubmed: 19748717
N Engl J Med. 1999 Dec 2;341(23):1725-30
pubmed: 10580071
Clin Kidney J. 2016 Oct;9(5):729-34
pubmed: 27679720
Kidney Int. 2001 Oct;60(4):1443-51
pubmed: 11576358
J Vasc Surg. 2008 Nov;48(5 Suppl):34S-47S
pubmed: 19000592
Nephrol Dial Transplant. 2013 Apr;28(4):991-7
pubmed: 23090982
Am J Kidney Dis. 2002 Oct;40(4):832-6
pubmed: 12324920
Kidney Int. 1993 May;43(5):1091-6
pubmed: 8510387
Clin J Am Soc Nephrol. 2014 Jul;9(7):1328-35
pubmed: 24509298
JAMA. 1993 Sep 15;270(11):1339-43
pubmed: 8360969
Clin J Am Soc Nephrol. 2010 Dec;5(12):2289-96
pubmed: 20876675
Nephrologie. 2003;24(7):353-8
pubmed: 14650746
Kidney Int Suppl. 2002 May;(80):49-54
pubmed: 11982813